# ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

> **NCT00325351** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 45 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Sagopilone (ZK 219477) + carboplatin

## Key facts

- **NCT ID:** NCT00325351
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-24
- **Primary completion:** 2008-07-08
- **Final completion:** 2009-03-25
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325351, "ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00325351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*